Momenta Wins Dismissal Of Blood-Clot Drug Antitrust Suit

Law360, Los Angeles (July 27, 2016, 9:43 PM EDT) -- A Massachusetts federal judge on Wednesday said that Amphastar Pharmaceuticals Inc. cannot bring federal antitrust claims against Momenta Pharmaceuticals Inc. for allegedly suppressing competition of sales of a generic blood clot drug because its alleged injury stems from a prior court-issued injunction, immunizing Momenta from suit.

Momenta and co-defendant Sandoz Inc., which together develop and manufacture enoxaparin — a generic life-saving anti-coagulant drug used in clinical settings to treat blood clots that is sold under the brand name Lovenox — are immunized from Amphastar’s antitrust claims...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.